期刊档案 · Medicine-Pharmacology (medical)
Drugs and Therapy Perspectives
ISSN 1172-0360 · eISSN 1179-1977 · Springer Nature · 12 issues per year
Drugs and Therapy Perspectives 中科院 医学 4区（2025 年升级版），影响因子 0.6（官网公布），订阅期刊，APC 约 3,490 美元，近 24 个月 22 篇文章投稿到接收中位 56 天，2025 年发文 86 篇，Scopus 收录。
研究范围
研究范围与定位
Drugs and Therapy Perspectives 由 Springer Nature 出版，属中科院医学大类（2025 升级版4区）。按 OpenAlex 近年发文统计，该刊主要发表 Pharmaceutical studies and practices、Pharmacovigilance and Adverse Drug Reactions、Pharmaceutical Practices and Patient Outcomes 等主题的论文，这 3 个主题约占 32.3%。（根据 OpenAlex 主题统计与中科院分区数据生成）
Drugs & Therapy Perspectives promotes rational pharmacotherapy and effective disease management by publishing concise, authoritative review articles to aid drug formulary and treatment decisions, and original research articles covering all aspects of pharmacological treatment to assist healthcare professionals in providing quality patient care. It focuses on the practical application of research and best evidence for healthcare professionals working in real-world clinical settings. The Journal includes: Reviews of pharmacological agents, disease management, adverse drug reactions and interactions, or other clinically relevant issues. These provide up-to-date guidance on the use of pharmacological agents in the real-world setting, including step-by-step patient care guidelines to aid treatment decisions, and the differential features of drugs to enable formulary comparisons. Original research articles with a strong focus on clinical practice and real-world outcomes to assist healthcare professionals in providing quality evidence-based patient care. Therapy-in-practice articles, current opinions and commentaries giving international viewpoints on emerging issues and therapeutic approaches to specific diseases or therapeutic questions.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：Medicine-Pharmacology (medical)
主编 Nitin Joshi Bpharm出版商官网
编委会国家分布：中国大陆 1 位（约 2%）；主要国家 美国 7、印度 5、澳大利亚 4、葡萄牙 4、沙特阿拉伯 3（共 44 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Pharmaceutical studies and practicesMedicine13.6%
- Pharmacovigilance and Adverse Drug ReactionsPharmacology, Toxicology and Pharmaceutics13.2%
- Pharmaceutical Practices and Patient OutcomesMedicine5.4%
- Pharmaceutical industry and healthcarePharmacology, Toxicology and Pharmaceutics4.2%
- Pharmacological Effects and Toxicity StudiesMedicine4.1%
- Asthma and respiratory diseasesMedicine4.1%
- Schizophrenia research and treatmentMedicine3.8%
- Economic, financial, and policy analysisEconomics, Econometrics and Finance3.8%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 4 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 4 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
数据库收录
ScopusLetPub
国际期刊预警名单：各版本均未列入LetPub
期刊官网自述收录
ESCIEmbase出版商官网
其他：Google Scholar、EBSCO、ProQuest、Dimensions、CNKI、Baidu、Naver、OCLC、Portico、CLOCKSS
期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子（出版商公布） 2025
- 0.6出版商官网 ·
- 五年影响因子（出版商公布） 2025
- 0.6出版商官网 ·
- CiteScore 2026-06
- 1LetPub ·
- SJR 2026-06
- 0.2LetPub ·
- SNIP 2026-06
- 0.18LetPub ·
- h-index
- 23OpenAlex ·
- i10-index
- 74OpenAlex ·
- 两年平均被引
- 0.57OpenAlex ·
- Gold OA 文章占比
- 0%LetPub ·
发文规模
- 年下载量（出版商公布） 2025
- 163,900出版商官网 ·
逐年发文量 OpenAlex 统计 · 累计 3,603 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 64 | 64 | 4 |
| 2025 | 86 | 26 | 37 |
| 2024 | 86 | 34 | 94 |
| 2023 | 64 | 27 | 85 |
| 2022 | 89 | 45 | 257 |
| 2021 | 77 | 29 | 250 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 Crossref 登记的稿件日期 · 至
56 天投稿到接收中位数 · P25–P75 33 天 – 113 天
- 接收到上线
- 中位数 23 天（82 篇）
- 投稿到上线
- 中位数 78 天
- 样本
- 22 篇有投稿与接收日期的文章（窗口内共 108 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 投稿到首次决定
- 8 天出版商官网 ·
- 评审方式
- 双盲同行评审出版商官网
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
订阅期刊LetPub
订阅期刊，文章需订阅或购买阅读，通常不收取版面费。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| OpenAlex | USD 3,490 / EUR 2,790 / GBP 2,390 | — | — |
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点4 项，摘自作者指南
- 摘要
- 150–250 词
- 参考文献格式
- 顺序编码制（按引用顺序编号）
- 推荐审稿人
- 可选
- 投稿信（Cover letter）
- 必须提供
接收的文章类型17 种
- current opinionCurrent Opinion. Word count approximately up to 3000. Places an area in perspective given that it is of current international interest and a consensus has not y…未说明篇幅
- editorialInternal Review by Editorial Staff: The journal editor will perform an initial appraisal of each manuscript. When submitting your paper, please include a coveri…未说明篇幅
- editorial/commentaryEditorial/Commentary. Word count up to 1500. A brief opinion piece on a current topic of high interest.未说明篇幅
- letter to the editorLetter to the Editor. Word count up to 1000. Comment on an article published recently in the journal; a response to the comments would normally be sought from t…未说明篇幅
- opinionThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…未说明篇幅
- original researchThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…未说明篇幅
- original research articleThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…未说明篇幅
- perspectiveThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…未说明篇幅
- protocolThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…未说明篇幅
- research articleThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…未说明篇幅
- reviewThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…未说明篇幅
- review articleThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…未说明篇幅
- short communicationThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…未说明篇幅
- short communicationsReports of studies that have investigated original approaches to clinical management but that are smaller in scale and, thus, may report pilot data warranting f…未说明篇幅
- summary of research article (sra)Summary of Research Article (SRA): A standalone summary of a source article previously published in an Adis journal, or in a journal from another publisher. The…未说明篇幅
- systematic reviewThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…未说明篇幅
- therapy in practiceTherapy in Practice. Word count up to 5000. Provides a succinct, clinically orientated guide to the optimum management of the disease/disorder/situation which h…未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、数据可用性、许可与版权、开放获取、试验注册 / 报告规范
- AI 使用 Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
原文 ↗出版商官网 ·- 作者资格 Authorship Principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
原文 ↗出版商官网 ·- 利益冲突 Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
原文 ↗出版商官网 ·- 数据可用性 Data availability statements
Data availability statement required for all original research 模型摘要
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
原文 ↗出版商官网 ·- 许可与版权 Copyright and license term – CC BY-NC
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution-NonCommercial 4.0 International License Find more about the license agreement Back to top
原文 ↗出版商官网 ·- 开放获取 Open access publishing
Open Choice articles published under CC BY-NC 4.0 模型摘要
To find out more about publishing your work Open Access in Drugs & Therapy Perspectives, including information on fees, funding and licences, visit our Open access publishing page. Back to top
原文 ↗出版商官网 ·- 试验注册 / 报告规范 Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Springer Nature
- 出版周期
- 12 issues per year
- ISSN
- 1172-0360
- 电子版 ISSN
- 1179-1977
- 官网最新一期
- Volume 42, Issue 1（2026 年 6 月）
- 官方链接
- 期刊主页 ↗OpenAlex
- 投稿系统 ↗LetPub
- 作者指南 ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
常见问题
关于 Drugs and Therapy Perspectives 的常见问题
Drugs and Therapy Perspectives 是中科院几区期刊？
2025 年升级版分区表中，Drugs and Therapy Perspectives 为医学 4区，小类 药学 4 区。2026 年新锐版分区表中为医学 4区。不同版本与大小类分区不能混用。
Drugs and Therapy Perspectives 的影响因子是多少？
期刊官网公布的影响因子为 0.6（2025 年度），属期刊自述数据，LetPub 暂无该刊的影响因子记录，CiteScore 为 1，h-index 为 23。
Drugs and Therapy Perspectives 的审稿周期多长？
按 2024年10月至2026年10月（近 24 个月）22 篇已发表文章登记的日期，投稿到接收的中位数为 56 天（四分位 33–113 天）。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Drugs and Therapy Perspectives 的投稿格式要求是什么？
据期刊作者指南：摘要：150–250 词；参考文献格式：顺序编码制（按引用顺序编号）；推荐审稿人：可选；投稿信：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Drugs and Therapy Perspectives 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 44 位编委中，中国大陆 1 位（约 2%）；人数最多的国家是 美国（7 位）、印度（5 位）、澳大利亚（4 位）。统计按编委会页面列出的机构国家计，仅供参考。
Drugs and Therapy Perspectives 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Drugs and Therapy Perspectives 被 Scopus 收录。期刊官网自述还被 ESCI、Embase 收录，该清单未与各数据库逐一核对。
Drugs and Therapy Perspectives 是开放获取期刊吗？版面费多少？
Drugs and Therapy Perspectives 为订阅期刊。APC 约 3,490 美元。
来源与更新
本页事实来自 LetPub、OpenAlex、出版商官网；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-25 归档）。最近更新：。